Contact This Organization


We are a medical device innovation company by surgeons for surgeons, addressing the single most important unmet need in wound closure - high suture tension. Suture under tension can damage skin, impair blood flow and cause skin necrosis. Our tension dispersing technology allows surgeons to offload incisions while allowing simple closure of challenging wounds that ordinarily require flaps, grafts, or are left open to heal naturally. Value is provided to the patient, who enjoys more rapid return to work/lifestyle, reduced risk. The provider can now bill for a closure they could not do otherwise, and the payor saves by having the most direct path from problem to solution, in an office setting
close more wounds and reduce risk of wound complications
Type of Organization
Startup - Newly established businesses, investable
Size of Organization
Organization Mailing Address

2397 NW Kings Blvd. Suite 235
Corvallis, OR 97330
United States

HEMIGARD Adhesive Retention Suture device
HEMIGARD is a novel disruptive technology that disperses suture tension away from the skin edge, allowing surgeons to use conventional suture at high tension and close many wounds that are usually not able to be closed, and instead require skin flaps or grafts, or natural wound care as they heal gradually over weeks or months. HEMIGARD is used intraoperatively and is left in place postoperatively for 2 weeks, supporting the wound during the high risk period where it may open (dehiscence).
Category of Innovation
Life Sciences - Life science solutions are those solutions that are delivered as a drug or device that typically require federal approval
Intended End User
Patient - Individuals who receive health care
Provider - Individuals or organizations responsible for providing care to patients (e.g. doctors, nurses, hospital/clinic administrators, etc.)
Payer - Organizations responsible for issuing or administering payment for the care received by a population of people (e.g. insurance companies)
Purchaser - Organizations responsible for purchasing health benefits for a population of people (e.g. employers or government entities)
Impactful Innovation Stage (Click Here for Details)
Problem (i.e. barrier, issue, complication, etc.) being solved for the end user
We need to get more eyes on the product. Once surgeons see them, most want to try, and when they do, they are likely to re-order the product
Idea/solution to the problem, if applicable
We want to scale our sales and marketing effort to address the above problem, and that requires funding. We would like to grow organically to get to self funding status and not seek VC or other leveraged financing to make progress. We know this will take time, but we are committed.
Level of adoption (i.e. list of customers/users, testimonials, etc.), if applicable
we have had >1000 uses by >100 surgeons. We have multiple testimonials from users and patients.
Impact (i.e. measurable outcomes), if applicable
Wounds have been closed that ordinarily wound not have been. This has obvious impact to the patient, provider and payor.
Funding Stage
List of Funding Sources (if applicable)
OSU accelerator, Business Oregon, founders, friends and family
FDA Class 1 registration x 2